ABSORICA LD Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Absorica Ld, and when can generic versions of Absorica Ld launch?

Absorica Ld is a drug marketed by Sun Pharm and is included in one NDA. There are two patents protecting this drug.

This drug has seventeen patent family members in nine countries.

The generic ingredient in ABSORICA LD is isotretinoin. There are thirteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the isotretinoin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Absorica Ld

A generic version of ABSORICA LD was approved as isotretinoin by AMNEAL PHARMS NY on September 29^th, 2017.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for ABSORICA LD?
What are the global sales for ABSORICA LD?
What is Average Wholesale Price for ABSORICA LD?

Summary for ABSORICA LD

International Patents:	17
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	73
Clinical Trials:	10
Patent Applications:	7,499
Drug Prices:	Drug price information for ABSORICA LD
DailyMed Link:	ABSORICA LD at DailyMed

Drug patent expirations by year for ABSORICA LD

Recent Clinical Trials for ABSORICA LD

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Children's Oncology Group	Phase 2
National Cancer Institute (NCI)	Phase 2
Ranbaxy Inc.	Phase 4

See all ABSORICA LD clinical trials

Pharmacology for ABSORICA LD

Drug Class	Retinoid

US Patents and Regulatory Information for ABSORICA LD

ABSORICA LD is protected by two US patents.

Patents protecting ABSORICA LD

Oral pharmaceutical composition of isotretinoin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Low dose oral pharmaceutical composition of isotretinoin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm	ABSORICA LD	isotretinoin	CAPSULE;ORAL	211913-001	Nov 5, 2019		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Sun Pharm	ABSORICA LD	isotretinoin	CAPSULE;ORAL	211913-004	Nov 5, 2019		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Sun Pharm	ABSORICA LD	isotretinoin	CAPSULE;ORAL	211913-002	Nov 5, 2019		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Sun Pharm	ABSORICA LD	isotretinoin	CAPSULE;ORAL	211913-006	Nov 5, 2019		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for ABSORICA LD

See the table below for patents covering ABSORICA LD around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2016016742		⤷ Sign Up
Japan	2017521470	イソトレチノインの経口医薬組成物	⤷ Sign Up
Russian Federation	2017106013		⤷ Sign Up
Brazil	112017001963		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration